The Prevalence of Vitamin D Deficiency in Patients With Alzheimer's Disease (DEVIT-ALZ)
|ClinicalTrials.gov Identifier: NCT01420315|
Recruitment Status : Completed
First Posted : August 19, 2011
Last Update Posted : February 18, 2013
|Condition or disease|
Vitamin D has many physiological functions via skeletal and extra-skeletal effects. Nowadays, it is well known that vitamin d deficiency causes to an increase in disease burden. As the role of vitamin D, the maintenance of balance, the improvement of muscle power, and the augmentation of innate immunity were proven. Some recent studies showed that vitamin D deficiency associates with cardiovascular diseases, autoimmune diseases, and the risk of cancer.
Vitamin D carries out your functions by vitamin d receptors (VDR) located in many cells. Brain neurons and glial cells are including VDR's. It is presumed that the functions of vitamin d in neurons are the regulation of neurotransmission, neuron protection, and immunomodulation. Also,vitamin D has a role in brain development and maturation. Except the functions in central nerve system, vitamin D has effects on peripheral nerve system. It was reported that nerve transduction velocity decreased in vitamin d deficiency.
Vitamin D deficiency and Alzheimer's disease are major public health problems that their incidences increase in advanced ages.Recent studies indicate that there is a relationship between cognitive decline and vitamin D deficiency. VDR receptors in brain specially in hippocampus, hypothalamus, limbic system, subcortical and spinal motor areas were determined.
Up to now, no study has investigated the prevalence of vitamin d deficiency in patient with Alzheimer's disease. Our aim is to investigate the prevalence of vitamin D deficiency and analysis the associated characteristics in patients with Alzheimer's disease.
|Study Type :||Observational|
|Actual Enrollment :||502 participants|
|Official Title:||The Prevalence of Vitamin D Deficiency in Patients With Alzheimer's Disease: a Crosssectional Multicenter Study in Turkey|
|Study Start Date :||August 2011|
|Primary Completion Date :||August 2012|
|Study Completion Date :||August 2012|
U.S. FDA Resources
- serum 25(OH)D levels [ Time Frame: January, 1, 2013 ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01420315
|Gulhane Medical School Training Hospital|
|Ankara, Turkey, 06018|
|Study Director:||Ilkin M Naharci, specialist||Gulhane Medical Faculty Training Hospital, Department of Internal Medicine, Division of Geriatrics|